Navigation Links
Northwest Bio to Present at Society of Neuro-Oncology Annual Meeting
Date:11/15/2011

Phase I trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax for recurrent metastatic ovarian cancer.  For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as r
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
2. Northwestern Memorial Transplant Program Initiates New Study
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
5. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
6. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
7. New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorials Bluhm Cardiovascular Institute
8. Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing
9. Swedish Cancer Institute and Elekta Launch Renewed Partnership Agreement to Continue the Flow of World-Class Technology, Services to Cancer Patients in the Pacific Northwest and Beyond
10. Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study
11. Northwestern Memorial Maintains Top Status in Nursing Hospital Renewed for Nurse Magnet®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ANTONIO , Jan. 15, 2014 Most osteoporosis ... according to a recent online survey* sponsored by Mission ... among the National Osteoporosis Foundation online support community, revealed ... take medication that comes in a form other than ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... Pharmaceuticals, Inc.  (Nasdaq: PCRX ) today announced ... from 381 U.S. hospitals who underwent common hospital-based surgical ... data demonstrate that opioid-related adverse events (ORAEs) are associated ... and more than a day increase in length of ...
... 2, 2011  WestPark Capital, Inc. announced the completion of ... total of 2,817,988 shares of common stock and warrants ... were sold, generating gross proceeds of $2,592,549 in the ... new applications for IsoRay,s Cesium-131 technology to treat lung, ...
Cached Medicine Technology:New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting 2New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting 3New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting 4WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering 2
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... donors was safe and effective in treating patients ... difficile , according to a new pilot study ... available online. Known as fecal microbiota transplantation, the ... colonoscope or a nasogastric tube. The findings suggest ... readily available to patients. , A growing concern, ...
(Date:4/23/2014)... National Institute of Arthritis and Musculoskeletal and Skin Diseases ... Ross Prize in Molecular Medicine, conferred by the Feinstein ... award will be given on June 9 at the ... scientific presentations by Dr. O,Shea and other prominent researchers. ... , The award, which includes a $50,000 prize from ...
(Date:4/23/2014)... LAFAYETTE, Ind. - Purdue University researchers have developed a ... living cell by using tiny gold particles with tails ... professor of agricultural and biological engineering, used gold nanoparticles ... known as BRCA1 messenger RNA splice variants, which can ... number of these mRNA splice variants in a cell ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... Work in primates points to possible weapon against human ... News) -- Researchers have successfully tested several Ebola vaccines ... first human vaccine for one of the world,s deadliest ... cannot be overlooked. We are seeing more and more ...
... has established that patients with a high blood pressure in ... of pumping blood against this pressure. Further, the right ventricle ... is the first Mosaic laureate to gain his doctorate. ... into the cause of high blood pressure in the lungs ...
... in French . , Montreal, March 31, 2008 ... a novel gene responsible for a significant fraction of ALS ... as Lou Gehrigs disease, an incurable neuromuscular disorder that affects ... to five years. , Published in the current online edition ...
... the manufacturer,of the SurgiLance safety lancet, has made ... Foundation (JDRF) to support ongoing research,efforts. MediPurpose made ... of its,500 millionth safety lancet to St. Louis-based ... improving the quality of life for those,living with ...
... 31 ReBuilder,Medical Technologies, Inc. (Pink Sheets: RBRM), ... diabetic peripheral neuropathy, Molluscum,Contagiosum, and MRSA; today reported ... when they sold over $25,000 in products., ... have not been affected thus far by the ...
... Highlights Key Issues and Offers Suggestions on ... Improvements for Hospital Administrators, NEW YORK, March ... delivery of a baby is a significant decision. But,there are ... departments,around the country that must function properly in order to ...
Cached Medicine News:Health News:Researchers Successfully Test Ebola Vaccines 2Health News:Researchers identify a gene responsible for Lou Gehrig's disease 2Health News:MediPurpose Supports Diabetes Research Effort 2Health News:ReBuilder Medical Technologies, Inc. Announces Best Sales Day in 5 Years 2Health News:OB Challenges Create Hospital Opportunities in 2008 2Health News:OB Challenges Create Hospital Opportunities in 2008 3Health News:OB Challenges Create Hospital Opportunities in 2008 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: